TP53 and cancer: Missense mutations in TP53 (mutp53) comprise >75% of all p53 alterations in cancer, resulting in highly stabilized mutant p53 proteins that not only lose their tumor-suppressor activity, but often acquire oncogenic gain-of-functions (GOFs).1, 2, 3, 4, 5 GOF activities promote cancer metabolism, stemness, and malignant progression and invasion.